| |
| |
|
| Insider
Information: |
Squinto Stephen P |
| Relationship: |
Director, 10% Owner |
| City: |
Cheshire |
| State: |
CT |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
238,160 |
|
|
Indirect Shares
|
6,290,493 |
|
|
| Direct
Value |
$19,437,710 |
|
|
|
Indirect Value
|
$19,013,945 |
|
|
| Total
Shares |
6,528,653 |
|
|
| Total
Value |
$38,451,655 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Alexion Pharmaceuticals Inc |
ALXN |
EVP, Chief Global Ops.... |
2014-10-27 |
106,508 |
2013-10-28 |
104,186 |
Premium* |
|
|
Springworks Therapeutics, Inc. |
SWTX |
Director, 10% Owner |
2022-05-19 |
131,652 |
2022-05-19 |
6,186,307 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
148 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of Research |
• – – |
2008-01-09 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
16,772 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2012-01-30 |
4 |
S |
$74.51 |
$223,828 |
D/D |
(3,004) |
74,662 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Head of Research |
• – – |
2004-11-02 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,600 |
28,126 |
|
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Global Ops. Officer |
• – – |
2014-02-06 |
4 |
S |
$155.11 |
$589,418 |
D/D |
(3,800) |
94,818 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Global Ops. Officer |
• – – |
2014-02-06 |
4 |
OE |
$93.83 |
$356,554 |
D/D |
3,800 |
98,618 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of Research |
• – – |
2008-10-29 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,852 |
31,165 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of Research |
• – – |
2008-10-30 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,852 |
27,313 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of Research |
• • – |
2005-03-09 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
15,876 |
|
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
officerTitle |
• – – |
2006-01-09 |
4 |
A |
$20.72 |
$82,880 |
D/D |
4,000 |
8,000 |
|
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of Research |
• – – |
2007-01-15 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
16,272 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Global Ops. Officer |
• – – |
2014-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
108,606 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of Research |
• – – |
2009-08-04 |
4 |
OE |
$32.25 |
$135,450 |
D/D |
4,200 |
32,451 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of Research |
• – – |
2009-08-04 |
4 |
AS |
$45.00 |
$189,000 |
D/D |
(4,200) |
28,251 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of Research |
• – – |
2006-04-07 |
4 |
A |
$0.00 |
$0 |
D/D |
4,272 |
12,272 |
|
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Head of R&D |
• – – |
2013-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
108,462 |
0 |
- |
|
| SWTX |
Springworks Therapeutics,... |
Director |
– • • |
2022-05-19 |
4 |
A |
$0.00 |
$0 |
D/D |
4,818 |
131,652 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
Executive VP |
• – – |
2003-10-02 |
4 |
AS |
$20.01 |
$100,050 |
D/D |
(5,000) |
30,077 |
|
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
Executive VP/Head of Research |
• – – |
2003-12-02 |
4 |
AS |
$20.20 |
$101,000 |
D/D |
(5,000) |
25,077 |
|
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
Executive VP/Head of Research |
• – – |
2004-02-09 |
4 |
AS |
$20.58 |
$102,875 |
D/D |
(5,000) |
20,476 |
|
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
Executive VP/Head of Research |
• – – |
2004-05-10 |
4 |
AS |
$21.01 |
$105,050 |
D/D |
(5,000) |
15,476 |
|
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Head of Research |
• – – |
2004-11-16 |
4 |
AS |
$20.82 |
$104,915 |
D/D |
(5,000) |
28,126 |
|
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Head of Research |
• – – |
2004-11-16 |
4 |
OE |
$2.38 |
$11,875 |
D/D |
5,000 |
33,126 |
|
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of Research |
• – – |
2006-02-15 |
4 |
AS |
$35.00 |
$175,116 |
D/D |
(5,000) |
8,000 |
|
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of Research |
• – – |
2006-02-15 |
4 |
OE |
$10.50 |
$52,500 |
D/D |
5,000 |
13,000 |
|
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2011-03-02 |
4 |
S |
$99.11 |
$495,550 |
D/D |
(5,000) |
39,637 |
0 |
- |
|
148 Records found
|
|
Page 3 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
